What changed
Added a separate product-identity check so evidence transfer is not confused with the distinct question of FDA approval.
Source record · Randomized trials and official regulatory records · reviewed July 26, 2026
Two ingredient names do not create the studied drug product.
The circulating claim“If semaglutide and cagrilintide are used together, that is basically CagriSema and the phase 3 results apply.”
What the source record says
CagriSema trials coadministered defined sponsor study products under controlled protocols; the proposed NDA product is a fixed-dose combination. Trial results do not authenticate separately obtained ingredients, an online blend, a compounded product, or a do-it-yourself mixture. CagriSema has been submitted to FDA but is not FDA-approved as of the July 26 review.
Why the claim misleads
The trials used identified study products under controlled protocols. Shared ingredient names do not establish the same formulation, quality controls, stability, sterility, handling, or product identity.
Correction
Two ingredient names do not create the studied drug product.
Primary sources
Garvey et al., 2025 — REDEFINE 1Open source ↗FDA concerns with unapproved GLP-1 drugsOpen source ↗Novo Nordisk — CagriSema NDA submissionOpen source ↗Cagrilintide / CagriSema library entryOpen source ↗What would change our answer
Product-level evidence would be required to authenticate another product. An FDA action could change CagriSema's status but would not by itself authenticate unrelated products.
Version history · 1 entry
- v1 · 2026-07-26Initial source-verified identity-transfer record.Source ↗
Boundary: This check evaluates a public claim. It does not assess an individual product or person and is not treatment, dosing, sourcing, or legal advice.